Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H26N2O.ClH |
Molecular Weight | 310.862 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCN1CCCC[C@@H]1C(=O)NC2=C(C)C=CC=C2C
InChI
InChIKey=NDNSIBYYUOEUSV-XFULWGLBSA-N
InChI=1S/C17H26N2O.ClH/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3;/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20);1H/t15-;/m1./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/9658202Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21550810 | https://www.ncbi.nlm.nih.gov/pubmed/18946303 | https://www.ncbi.nlm.nih.gov/pubmed/3239398
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9658202
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21550810 | https://www.ncbi.nlm.nih.gov/pubmed/18946303 | https://www.ncbi.nlm.nih.gov/pubmed/3239398
(R)-Ropivacaine (Dextroropivacaine) is a voltage-dependent potassium channel blocker with local anesthetic activity. (S)-Ropivacaine is a medication used for the production of local or regional anesthesia for surgery and for acute pain management. Ropivacaine shows a difference in channel blockade between two enantiomers, and R-Ropivacaine shows greater cardiotoxicity than (S)-Ropivacaine. (R)-Ropivacaine is the impurity in commercial formulations of Ropivacaine.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2309 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18946303 |
135.0 µM [IC50] | ||
Target ID: CHEMBL4306 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9658202 |
32.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Structural determinants of potency and stereoselective block of hKv1.5 channels induced by local anesthetics. | 1998 Jul |
|
Ropivacaine in the horse: its pharmacological responses, urinary detection and mass spectral confirmation. | 2001 Apr |
|
[Ropivacaine 0.2% versus bupivacaine 0.125% plus sufentanil for continuous peridural analgesia following extended abdominal operations]. | 2001 Apr |
|
Caudal ropivacaine in infants: population pharmacokinetics and plasma concentrations. | 2001 Apr |
|
Intrathecal ropivacaine and clonidine for ambulatory knee arthroscopy: a dose-response study. | 2001 Apr |
|
[Assessment of nociceptive suppression in laparoscopic postoperative status: prospective, randomized and comparative study with a control group]. | 2001 Aug |
|
[Evaluation of antibacterial filters for peridural obstetrical anesthesia]. | 2001 Aug |
|
An evaluation of the infraclavicular block via a modified approach of the Raj technique. | 2001 Aug |
|
Simultaneous determination of unbound ropivacaine in rat blood and brain using microdialysis. | 2001 Aug 25 |
|
Spinal anaesthesia with ropivacaine 5 mg ml(-1) in glucose 10 mg ml(-1) or 50 mg ml(-1). | 2001 Feb |
|
Effects of bupivacaine and ropivacaine on high-voltage-activated calcium currents of the dorsal horn neurons in newborn rats. | 2001 Jul |
|
Effect of ropivacaine on platelet function. | 2001 Jul |
|
Developments in local anaesthetic drugs. | 2001 Jul |
|
Pharmacokinetics and analgesic effect of ropivacaine following ilioinguinal/iliohypogastric nerve block in children. | 2001 Jul |
|
A comparison of five solutions of local anaesthetics and/or sufentanil for continuous, postoperative epidural analgesia after major urological surgery. | 2001 Jul |
|
A comparison of 1% prilocaine with 0.5% ropivacaine for outpatient-based surgery under axillary brachial plexus block. | 2001 Jul |
|
The effects of single or multiple injections on the volume of 0.5% ropivacaine required for femoral nerve blockade. | 2001 Jul |
|
Hyperbaric spinal ropivacaine for cesarean delivery: a comparison to hyperbaric bupivacaine. | 2001 Jul |
|
The dose-response relationship for clonidine added to a postoperative continuous epidural infusion of ropivacaine in children. | 2001 Jul |
|
Postoperative analgesia by combined continuous infusion and patient-controlled epidural analgesia (PCEA) following hip replacement: ropivacaine versus bupivacaine. | 2001 Jul |
|
Low dose intrathecal ropivacaine with or without sufentanil provides effective analgesia and does not impair motor strength during labour: a pilot study. | 2001 Jul-Aug |
|
Does alkalinization of 0.75% ropivacaine promote a lumbar peridural block of higher quality? | 2001 Jul-Aug |
|
Clinical usefulness, safety, and plasma concentration of ropivacaine 0.5% for inguinal hernia repair in regional anesthesia. | 2001 Jul-Aug |
|
Efficacy of varying concentrations of hyaluronidase in peribulbar anaesthesia. | 2001 Jun |
|
Convulsions after the administration of high dose ropivacaine following an interscalenic block. | 2001 Jun |
|
Clonidine as adjuvant for mepivacaine, ropivacaine and bupivacaine in axillary, perivascular brachial plexus block. | 2001 Jun |
|
Minimum local analgesic dose of plain ropivacaine vs. ropivacaine combined with sufentanil during epidural analgesia for labour. | 2001 Jun |
|
Postoperative pain control using epidural catheters after anterior spinal fusion for adolescent scoliosis. | 2001 Jun 1 |
|
Effects of bupivacaine and ropivacaine on hemodynamic parameters in rabbits. | 2001 Mar |
|
Differences of ropivacaine and bupivacaine relevant to antiinflammatory activity, platelet aggregation and antioxidant activity in vitro. | 2001 Mar |
|
Double-blind comparison of ropivacaine 7.5 mg ml(-1) with bupivacaine 5 mg ml(-1) for sciatic nerve block. | 2001 May |
|
[The effects of peridural anesthesia on duration of labor and mode of delivery]. | 2001 May |
|
[Peripheral nerve block. An overview of new developments in an old technique]. | 2001 May |
|
[Comparison of ropivacaine and bupivacaine for epidural analgesia during labor]. | 2001 May |
|
Dose-response study of epidural ropivacaine for labor analgesia. | 2001 May |
|
Improving postoperative analgesia after axillary brachial plexus anesthesia with 0.75% ropivacaine. A double-blind evaluation of adding clonidine. | 2001 May |
|
Direct injection of human plasma samples after ultrafiltration into programmed temperature vaporiser-gas chromatography-mass spectrometry with packed liner. | 2001 May 5 |
|
[Clinical and pharmacological characteristics of ropivacaine in sacral anesthesia]. | 2001 May-Jun |
|
Ropivacaine with or without clonidine improves pediatric tonsillectomy pain. | 2001 Oct |
|
A new posterior approach to the sciatic nerve block: a prospective, randomized comparison with the classic posterior approach. | 2001 Oct |
|
The pharmacokinetics of epidural ropivacaine in infants and young children. | 2001 Oct |
|
Antimicrobial activity of ropivacaine and other local anaesthetics. | 2001 Oct |
|
A comparison of 0.5% ropivacaine and 1% mepivacaine for sciatic nerve block in the popliteal fossa. | 2001 Sep |
|
Ropivacaine 0.2% and lidocaine 0.5% for intravenous regional anesthesia in outpatient surgery. | 2001 Sep |
|
Post-thoracotomy analgesia. | 2001 Sep |
|
Systemic toxicity and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats. | 2001 Sep |
|
Interscalene brachial plexus block with continuous intraarticular infusion of ropivacaine. | 2001 Sep |
|
Preincisional intravenous low-dose ketamine and local infiltration with ropivacaine reduces postoperative pain after laparoscopic cholecystectomy. | 2001 Sep |
|
Stability and compatibility of methylprednisolone acetate and ropivacaine hydrochloride in polypropylene syringes for epidural administration. | 2001 Sep 15 |
|
Analgesic effects of low-dose ropivacaine for interscalene brachial plexus block for outpatient shoulder surgery-a dose-finding study. | 2001 Sep-Oct |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18946303
Human embryonic kidney 293 cells stably expressed human Kv1.1 channels were used for activity evaluation. Whole cell currents were measured with the voltage clamp method of the patch clamp technique using an EPC-9 amplifier. The currents were filtered at 1 kHz, and series resistance was actively compensated by at least 80%. A p/4 leak subtraction protocol was used in the study, with the exception of the experiments for frequency dependence. The patch electrodes were fabricated from borosilicate glass capillary tubes with filament using a Sutter P-97 puller. The pipettes had a
resistance of 2–4 M and were filled with a solution containing the following electrolyte concentrations: 160 mM KCl, 0.5 mM MgCl2, 10 mM HEPES, and 2 mM Na2ATP, with a pH of 7.25 adjusted with KOH. The extracellular solution consisted of 135 mM NaCl, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 5 mM HEPES, 10 mM sucrose, and 0.01 mg/ml phenol red, with a pH of 7.4 adjusted with NaOH. All experiments were performed at room temperature.
Dextroropivacaine was dissolved in the watery extracellular solution, yielding stock solutions of 1 mM and drug was applied on the cells by a perfusion system at concentrations 10mkM-1000mkM.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
MI262Q4RJI
Created by
admin on Sat Dec 16 08:01:46 GMT 2023 , Edited by admin on Sat Dec 16 08:01:46 GMT 2023
|
PRIMARY | |||
|
DTXSID40150174
Created by
admin on Sat Dec 16 08:01:46 GMT 2023 , Edited by admin on Sat Dec 16 08:01:46 GMT 2023
|
PRIMARY | |||
|
71752106
Created by
admin on Sat Dec 16 08:01:46 GMT 2023 , Edited by admin on Sat Dec 16 08:01:46 GMT 2023
|
PRIMARY | |||
|
112773-90-7
Created by
admin on Sat Dec 16 08:01:46 GMT 2023 , Edited by admin on Sat Dec 16 08:01:46 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD